ILMN Illumina, Inc.
ILMN Illumina, Inc.
Healthcare · Diagnostics & Research
Desk view
Market read
Scan convergence 2 scans as of 2026-08-17 2 bull converging
POC $120.23 · VWAP $136.79 · +41.2% vs 12m avg buyer
Insiders selling 0 buy / 8 sell · Form 4, 90d latest sell Meister Keith A.
Coverage
4 watchlists
ILMN Price Structure
Loading timeframes…
Peers
Every watchlist ILMN belongs to, members best 30-day change first — ILMN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
@biotech-scan
@focus
Reported the quarter ending 2026-06-28: revenue $1.16B, diluted EPS $1.35, net income $207M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved +5.3% (close before → first close after).
full note →Against street estimates
How ILMN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ILMN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 3 days ago · Aug 15
- A Look At Illumina (ILMN) Valuation After Profitability Gains And SomaLogic Acquisition Guidance
- Illumina completes acquisition of SomaLogic from Standard BioTools
- Illumina Inc (ILMN) 10-K Annual Report February 2026
- Illumina Inc (ILMN) 8-K Earnings Release - Feb 2026
- Illumina completes acquisition of SomaLogic from Standard BioTools
ILMN research tape
51 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.